A5006671522- Prostate Cancer Treatment and Research
- PARP inhibition in cancer therapy
- Multiple Myeloma Research and Treatments
- Bladder and Urothelial Cancer Treatments
- Renal cell carcinoma treatment
- Protein Degradation and Inhibitors
- Urinary and Genital Oncology Studies
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Prostate Cancer Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- DNA Repair Mechanisms
- Pancreatic and Hepatic Oncology Research
- Chronic Lymphocytic Leukemia Research
- Renal and related cancers
- Lymphoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Venous Thromboembolism Diagnosis and Management
- Lung Cancer Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Lung Cancer Treatments and Mutations
- Cell death mechanisms and regulation
- Radiation Effects in Electronics
- Advanced Breast Cancer Therapies
Clinique Victor Hugo
2016-2025
Centre Jean Bernard
2016-2025
Western University
2024
Centre Hospitalier du Mans
2012-2021
Hôpital Saint-Louis
2020
Assistance Publique – Hôpitaux de Paris
2020
Inserm
2013
Centre Hospitalier Universitaire de Nantes
2012
Roche (France)
2007
Hôpital Européen Georges-Pompidou
2005-2007
Platinum-based chemotherapy is standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall are limited by resistance.
BRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors. We present results from patients mCRPC associated a BRCA alteration treated rucaparib 600 mg twice daily the phase II TRITON2 study.We enrolled who progressed after one two lines of next-generation androgen receptor-directed therapy taxane-based chemotherapy for mCRPC. Efficacy safety populations included...
Purpose In multiple myeloma, many prognostic parameters have been proposed. However, all of these predict shorter survival. To identify patients with a longer life expectancy, we updated the data treated in IFM (Intergroupe Francophone du Myelome) 99-02 and 99-04 trials. Patients Methods A series 520 was analyzed. Median follow-up 90.5 months. perform comprehensive analysis major factors, reanalyzed for 1q gains [in addition to updating del(13), t(4;14), del(17p) analyses]. Results It...
Abstract Preclinical evidence has suggested an interplay between the androgen receptor, which largely drives growth of prostate cancer cells, and poly(ADP-ribose) polymerase. This association provides a rationale for their co-inhibition treatment metastatic castration-resistant (mCRPC), area unmet medical need. The phase 3 TALAPRO-2 study investigated combining polymerase inhibitor talazoparib with enzalutamide versus alone as first-line mCRPC. Patients were prospectively assessed tumor...
LBA18 Background: The Phase 3 TALAPRO-2 trial met its primary endpoint, showing improved radiographic progression-free survival (rPFS) for TALA + ENZA vs placebo (PBO) as 1L treatment in pts with mCRPC unselected homologous recombination repair (HRR) gene alterations (all-comers; cohort 1). Here we report final OS data, a descriptive update of rPFS, and extended safety follow-up 1. Methods: In 1, were randomized 1:1 to 160 mg either 0.5 (0.35 if moderate renal impairment) or PBO once daily...
Merkel cell carcinoma (MCC) is a highly malignant skin neoplasm. Regional lymph node and distant metastasis occur in 20-52% of patients. The role chemotherapy the treatment patients with this rare tumor unclear.An exhaustive analysis literature (1980-1995) describing for locally advanced or metastatic MCC was performed. All available published medical records (n = 101 patients) were entered database. In addition, data on six additional given during time frame Lyon, France, included...
We retrospectively compared survivals in patients with a lung cancer history and followed by the so-called sentinel Web-application that allows early detection of relapse palliative care initiation versus conventional follow-up our center.The survival 98 consecutive was assessed. The first part them (the control arm) recruited between March 2011 August 2012. second half experimental prospectively 2012 December 2013 to weekly fill form 11 self-assessed symptoms, then processed "sentinel"...
LBA1 Background: Platinum-based chemotherapy is an active 1L regimen for advanced UC; however, progression-free survival (PFS) and overall (OS) are generally short because of resistance. This randomized, phase 3 trial (JAVELIN Bladder 100; NCT02603432) evaluated avelumab (anti–PD-L1) as maintenance therapy following response or stable disease with platinum-based in patients UC. Methods: Eligible unresectable locally metastatic UC without progression after 4-6 cycles gemcitabine either...
LBA17 Background: TALAPRO-2 (NCT03395197) is the first phase 3 study to combine poly(ADP-ribose) polymerase inhibitor TALA with androgen receptor ENZA. Pts unselected for genetic alterations in DNA damage repair pathways, directly or indirectly involved homologous recombination (HRR), received either + ENZA PBO as 1L treatment mCRPC. Methods: randomized 1:1 0.5 mg (all pts 160 daily) were stratified by prior abiraterone docetaxel castration-sensitive PC and HRR gene alteration status. Key...
In the phase 3 JAVELIN Bladder 100 trial, avelumab first-line (1L) maintenance + best supportive care (BSC) significantly prolonged overall survival (OS) and progression-free (PFS) versus BSC alone in patients with advanced urothelial carcinoma (aUC) who were following 1L platinum-based chemotherapy, leading to regulatory approval various countries.
561 Background: Avelumab 1LM is the standard of care for aUC that has not progressed with 1L platinum-based chemotherapy based on level 1 evidence from JAVELIN Bladder 100 phase 3 trial. Previous results AVENANCE showed effectiveness and safety avelumab in a real-world population France. We report updated data analyses by subsequent (next-line) treatment. Methods: (NCT04822350) noninterventional, ambispective study. Eligible pts had previous, ongoing, or planned The primary endpoint overall...
LBA141 Background: Approximately one-quarter of advanced prostate cancers have alterations in DNA damage response genes directly or indirectly involved with HRR that can sensitize them to treatment poly(ADP-ribose) polymerase inhibitors. The Phase 3 TALAPRO-2 trial met its primary endpoint, showing improved radiographic progression-free survival (rPFS) for TALA + ENZA vs placebo (PBO) as 1L pts mCRPC the HRR-deficient cohort (cohort 2). At first interim analysis, immature OS data favored PBO...
Mitoxantrone-corticosteroid is currently the standard palliative treatment in hormone-refractory prostate cancer (HRPC) patients. Recent clinical trials documented high activity of docetaxel-estramustine combination. We conducted a randomized phase II study to evaluate prostate-specific antigen (PSA) response (primary end point) and safety two docetaxel-estramustine-prednisone (DEP) regimens mitoxantrone-prednisone (MP).One hundred thirty metastatic HRPC patients were randomly assigned...